These agents act on vagal afferents, the hypothalamus, and the hindbrain, suppressing food intake and reducing body weight
GLP-1RA Reward Behaviour Systematic Review (PubMed, 2024) GLP-1 Receptor Signalling in Reward Circuitry, Dopamine, and Addiction Research A systematic review of GLP-1 receptor agonist effects on reward behaviour published on PubMed following PRISMA guidelines across OVID, PubMed, Scopus, and Google Scholar evaluated the evidence for GLP-1Rs role in reward dysfunction across obesity, type 2 diabetes, and psychiatric conditions
For consumers who have struggled with conventional diet and exercise approaches, the Slimpic narrative suggests that their difficulties may be rooted in a gut microbiome imbalance, rather than personal discipline, is both scientifically plausible and emotionally validating
US Food and Drug Administration (FDA) Approvals of GLP-1 and GLP1 /GIP RAs 11,22-34 However, these labels are being expanded to include additional indications for patients with a spectrum of other cardiometabolic conditions, such as obesity, cardiovascular disease, chronic kidney disease, and obstructive sleep apnea
Feature selection was performed using a combination of SelectKBest with ANOVA F-values and model-specific importance scores
These medications slow gastric emptying to improve blood sugar control and promote weight loss, but this same mechanism may contribute to reflux symptoms
